Changes in Hong Kong stocks | Chuangsheng Group Pharmaceutical-B (06628) rose by more than 24%, and Chairman of the Board Qian Xueming increased his holdings in the company's shares and foreign licensing revenue increased in the first half of the year

The Zhitong Finance App learned that Chuangsheng Group Pharmaceutical-B (06628) rose more than 24% in the intraday period. As of press release, it had risen 24.1% to HK$1.21, with a turnover of HK$5,013,300.

According to the news, according to the latest data from the Hong Kong Stock Exchange, on September 17, Qian Xueming increased his holdings of Chuangsheng Group Pharmaceutical-B by 100,000 shares, at a price of HK$0.8552 per share, for a total amount of HK$85,52 million. The latest number of shares held after the increase was 38.60 million shares, and the latest shareholding ratio was 8.47%.

Earlier, Chuangsheng Group Pharmaceutical-B disclosed the 2026 interim results. The group obtained revenue of 235.97 million yuan, an increase of 770.42% over the previous year; the loss attributable to the company's owners was 67.347 million yuan, a year-on-year decrease of 38.66%; and a loss of 0.27 yuan per share. Loss of $0.16 per share. According to the announcement, the increase in revenue was mainly due to an increase in foreign licensing revenue and CDMO services.